Abstracts tagged "Joint Structure"

Abstract Number: 2029 • ACR Convergence 2025
Characteristics of a Historical Cohort of Adult Patients with Juvenile Idiopathic Arthritis
Francina salabert-Carreras¹, Raquel Ugena-García², Cristina Rocamora-Gisbert³, Cristina Calomarde-Gómez², Clara Churtichaga Domenech¹, Judith Vidal ripoll¹, LOURDES MATEO SORIA⁴, Laia Gifre-Sala¹, Maria Aparicio³, Susana Holgado⁵, Águeda Prior Español¹, Anne Riveros frutos³, Ivette Casafont-Solé², Eva Forcadell Pirretas¹, Anna Pujol Manresa¹, Judit Font-Urgelles², Melania Martínez-Morillo¹ and Annika Nack³, ¹Hospital Germans Trias i Pujol, Barcelona, ²Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ³Hospital Germans Trias i Pujol, Barcelona, Spain, ⁴HOSPITAL GERMANS TRIAS I PUJOL, BADALONA, Spain, ⁵Hospital Germans Trias i Pujol, Barcelona, Catalonia, Spain
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. Up to one-third of patients experience disease flares in adulthood, with…
Abstract Number: 1970 • ACR Convergence 2025
Comparison of Optical Imaging with Musculoskeletal Ultrasound in Assessment of PIP Joints of Systemic Lupus Erythematosus Patients
Wei Tang¹, Giovanna Rosas Chavez², Leila Khalili², Alberto Nordmann-Gomes³, Stephen Suh⁴, Alessandro Marone⁵, Moegammad Bardien⁵, Stephen Kim⁵, Laura Geraldino-Pardilla⁶, Andreas Hielscher⁵ and Anca Askanase², ¹Westchester Medical Center, Valhalla, NY, ²Columbia University Medical Center, New York, NY, ³Columbia University Irving Medical Center, New York, NY, ⁴Columbia University Irving Medical Center, New York City, NY, ⁵New York University Tandon School of Engineering, New York, NY, ⁶Columbia University, New York, NY
Background/Purpose: Lupus arthritis has heterogeneous phenotypes and severity, complicating clinical management and trial endpoints. Advances in musculoskeletal ultrasound (MSK US) and optical imaging have been…
Abstract Number: 1936 • ACR Convergence 2025
A Fully Automated Method for Measuring Minimum Tibiofemoral Joint Space Width in Knee Osteoarthritis Assessment: Data from the FNIH cohort
Ahmad Almhdie-Imjabbar¹, Yousra TOUZANI², Hechmi Toumi² and Eric Lespessailles³, ¹University Hospital Center of Orleans, Orleans, France, ²PRIMMO- University Hospital Center of Orleans, Orleans, France, ³CHU Orléans, Orléans, France
Background/Purpose: Osteoarthritis is one of the most prevalent chronic diseases worldwide, with knee osteoarthritis (KOA) being a particularly painful and debilitating form. The minimum tibiofemoral…
Abstract Number: 1737 • ACR Convergence 2025
CR10049, the first intra-articular Src family kinase inhibitor as a long-acting symptom- and disease-modifying drug for the inflammatory OA phenotype
Luigino Giancotti, Tiziana Piepoli, Roberto Artusi, Matteo Ghirri, Michela Visintin, Gianfranco Caselli and Lucio Rovati, Rottapharm Biotech, Monza, Italy
Background/Purpose: The inflammatory osteoarthritis (OA) phenotype is characterized by the presence of synovial membrane inflammation, pain and pathological changes in joint structure leading to rapid…
Abstract Number: 1137 • ACR Convergence 2025
Increased Risk of Cardiovascular Events and Mortality Related to Diffuse Idiopathic Skeletal Hyperostosis (DISH): A Systematic Review and Meta-Analysis
Pitchaporn Yingchoncharoen¹, Nattanicha Chaisrimaneepan², Miriam Paz³, Chanokporn Puchongmart¹, Ben thiravetyan¹, Panat Yanpiset¹ and Jerapas Thongpiya⁴, ¹Texas Tech Health Sciences Center, Lubbock, TX, ²Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ³Texas Tech University Health Sciences Center, Lubbock, ⁴Texas Tech University Health Sciences Center at Lubbock Program, Lubbock, TX
Background/Purpose: Diffuse Idiopathic Skeletal Hyperostosis (DISH) is characterized by ossification and calcification of the entheses with prevalence increasing with age. It has been reported to…
Abstract Number: 0426 • ACR Convergence 2025
Tofacitinib in Juvenile Idiopathic Arthritis: efficacy and safety in a clinical practice setting.
Vicenç Torrente-Segarra¹, Andrea Zacarias², Cynthia Rojas³, Jordi Antón-López², Judith Sanchez⁴ and Meritxell Salles Lizarzaburu⁵, ¹Hospital Comarcal Alt Penedés Garraf, Vilafranca del Penedès, Spain, ²Pediatric Rheumatology Department, Hospital Sant Joan de Déu, Barcelona (Spain)., Barcelona, Spain, ³Rheumatology Department, Hospital Comarcal Alt Penedès Garraf, Vilafranca del Penedès (Spain)., Vilafranca del Penedes, Spain, ⁴Pediatric Rheumatology Department, Taulí Hospital Universitari-Institut d'Investigació i Innovació Parc Taulí (I³PT-CERCA), Sabadell (Spain)., Sabadell, Spain, ⁵Rheumatology Department, Althaia Xarxa Assistencial Universitària Manresa Manresa (Spain)., Manresa, Spain
Background/Purpose: This study aims to evaluate the efficacy and safety of tofacitnib, a JAK inhibitor, in a multicentric cohort of patients with juvenile idiopathic arthritis…
Abstract Number: 2104 • ACR Convergence 2025
Pain 0-10 visual analog scale (VAS) and RAPID3 (routine assessment of patient index data) in OA and RA are similar in 2024 to 1979 and 1989
Theodore Pincus¹, Tengfei Li² and Juan Schmukler¹, ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: A 1979 report by Huskisson, who developed the 0-10 pain visual analog scale (VAS) , entitled "Another look at osteoarthritis" indicated mean pain VAS…
Abstract Number: 2086 • ACR Convergence 2025
WOMAC Physical Function and 3D MRI Bone Shape: Advancing a “Virtual” Total Knee Replacement Endpoint for Knee Osteoarthritis Clinical Trials
Dawn McGuire¹, Alan Brett², Neil Segal³, Meghan Miller⁴, David Rosen¹ and Yoshi Kumagai⁵, ¹OrthoTrophix, Inc, Foster City, CA, ²Imorphics, Manchester M²⁰ ²HJ, England, United Kingdom, ³KUMC, Kansa City, KS, ⁴OrthoTrophics, Foster City, CA, ⁵OrthoTrophix, Foster City, CA
Background/Purpose: TPX-100, a peptide derived from matrix extracellular phosphoglycoprotein (MEPE), is in development as a potential disease-modifying osteoarthritis drug (DMOAD) for mild to severe knee…
Abstract Number: 0792 • ACR Convergence 2024
Radiographic and Pain Outcomes from a Phase 3 Trial (OA-07) Evaluating the Efficacy and Safety of Repeat Lorecivivint Injections over 3 Years in Subjects with Knee OA
Yusuf Yazici¹, Jeyanesh Tambiah², Christopher Swearingen³ and Timothy McAlindon⁴, ¹NYU Grossman School of Medicine, La Jolla, CA, ²Biosplice Therapeutics Inc., San Diego, CA, ³Biosplice Therapeutics, Inc, San Diego, CA, ⁴University of Massachusets, Worchester, MA
Background/Purpose: Knee OA has unmet need for safe and efficacious symptom and disease-modifying treatments. Lorecivivint (LOR), an intra-articular (IA) CLK/DYRK inhibitor thought to modulate inflammatory…
Abstract Number: 0926 • ACR Convergence 2024
Macrophages and Nociceptor Neurons Form a Sentinel Unit Around Fenestrated Capillaries to Defend the Synovium from Systemic Challenges
Tetsuo Hasegawa and Menna Clatworthy, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: A wide variety of systemic pathologies, including infectious and autoimmune diseases, are accompanied by joint pain or inflammation, often mediated by circulating immune complexes…
Abstract Number: 1180 • ACR Convergence 2024
Relationship Between Changes in Physical Activity and Early Onset Knee Osteoarthritis in Individuals After ACL Reconstruction
David Werner¹, Yvonne Golightly¹, Michael Rosenthal¹, Balasrinivasa Sajja¹, Christopher Wichman¹, Melissa Manzer², Matthew Tao¹ and Elizabeth Wellsandt¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Private Practice, Omaha
Background/Purpose: Low physical activity levels are associated with osteoarthritis (OA) development and progression in individuals at risk for OA development. Including both structural and symptomatic…
Abstract Number: 1184 • ACR Convergence 2024
Sustained Clinical Effects After a Single Intra-articular Injection of PCRX-201 for Moderate-to-Severe Osteoarthritis of the Knee
Stanley Cohen¹, Philip G Conaghan², Marc Hochberg³, Alan Kivitz⁴, Nino Joy⁵, Derek Jackson⁵, Masato Nakazawa⁵, Mary DiGiorgi⁵ and Jonathan Slonin⁵, ¹Metroplex Clinical Research Center, dallas, TX, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³University of Maryland School of Medicine, Baltimore, MD, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Pacira BioSciences, Inc., Tampa, FL
Background/Purpose: Osteoarthritis of the knee (OAK) is a common and severe disease. Current treatments provide temporary pain relief, demonstrating unmet need. PCRX-201 is a high…
Abstract Number: 1551 • ACR Convergence 2024
Efficacy of Belimumab on Different Phenotypes of Joint and Skin Manifestations of Systemic Lupus Erythematosus: Preliminary Data from a Multicenter, Nationwide, Cohort of Patients: The BElimumab in Real Life Setting Study-New Joint and Skin (BeRLISS-NeJS)
Luca Iaccarino¹, Marisol Bracalenti², Alberto Cauli³, Lorenzo Cavagna⁴, Rossella De Angelis⁵, Roberto Depascale², Giacomo Emmi⁶, Roberto Gerli⁷, Marcello Govoni⁸, Alberto Lo Gullo⁹, Simone Negrini¹⁰, Luca Quartuccio¹¹, Maurizio Rossini¹², Carlo Salvarani¹³, Paola Tomietto¹⁴, Angelo Vacca¹⁵, Margherita Zen¹⁶ and doria Andrea², ¹University of Padua, PADOVA, Italy, ²University of Padova, Padova, Italy, ³University of Cagliari, Cagliari, Italy, ⁴University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, ⁵Università Politecnica delle Marche, Ancona, Italy, ⁶University of Trieste, Trieste, Italy, ⁷University of Perugia, Perugia, Italy, ⁸Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy, Ferrara, Italy, ⁹Rheumatology Unit, Papardo Hospital, Messina, Italy, ¹⁰University of Genova, Genova, Italy, ¹¹Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, ¹²Rheumatology Unit, University of Verona, Verona, Italy, ¹³Azienda USL-IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, ¹⁴Azienda Sanitaria Universitaria Giuliano Isontina, trieste, Italy, ¹⁵University of Bari, Bari, Italy, ¹⁶University of Padova, Padova, Padua, Italy
Background/Purpose: To evaluate the efficacy of belimumab on different skin and joint manifestations of the disease in a multicenter, nationwide, cohort (BeRLISS-NeJS) of patients with…
Abstract Number: 2050 • ACR Convergence 2024
Clinical Enthesitis Concerns Half the Patients with Psoriatic Arthritis, Is More Frequent in Trials Than in Observational Studies and Is Assessed Heterogeneously: A Systematic Review with Meta-analysis of 84,262 Patients from 212 Studies
caroline pignon¹, Laure Gossec², Bruno Fautrel³, Clementina López Medina⁴ and Noemie bibas⁵, ¹Faculté de médecine Créteil, PARIS, France, ²Sorbonne Université, Paris, France, ³INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, ⁴Reina Sofia University Hospital, Cordoba, Spain, ⁵Sorbonne Université, paris
Background/Purpose: Enthesitis is considered a hallmark of psoriatic arthritis (PsA), however data on the frequency and consequences of enthesitis are conflicting. To analyze clinical enthesitis in…
Abstract Number: 2099 • ACR Convergence 2024
A Longitudinal Study of Infrapatellar Fat Pad Morphologies as Predictive Markersin Knee Osteoarthritis
Jean-Pierre Pelletier¹, Patrice Paiement¹, François Abram², Marc Dorais³ and Johanne Martel-Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Osteoarthritis Research Unit, University of Montreal Hospital Research Center (CRCHUM), Montreal, QC, Canada, ³StatSciences Inc., Notre-Dame de l'Île-Perrot, QC, Canada
Background/Purpose: Currently, no established marker effectively stratifies knee osteoarthritis (OA) patients into subgroups. The infrapatellar fat pad (IPFP) has been proposed as a potential key…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].